Actively Recruiting
Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration
Led by Gee-Chen Chang · Updated on 2025-09-10
6618
Participants Needed
7
Research Sites
315 weeks
Total Duration
On this page
Sponsors
G
Gee-Chen Chang
Lead Sponsor
A
AstraZeneca
Collaborating Sponsor
AI-Summary
What this Trial Is About
Lung cancer is the leading cause of mortality in the world, and also in Taiwan.Despite the researches and availability in new therapies, it causes the highest mortality and is one of the most preventable cancers as well. Smoking is the most common cause of lung cancer worldwide. Compared to lung cancer in smokers, lung cancer in never-smokers is associated with East Asian ethnicity, female sex, and adenocarcinoma histology. This unique risk group is likely to have distinct molecular drivers, especially EGFR, ALK, and ROS1 mutations.In National Taiwan Cancer Registry data, more than half (53%) of all newly diagnosed lung cancer patients and 93% of female patients are lifelong never-smokers. This scenario is common in East Asia. It is essential to develop a different strategy for screening lung cancer patients with other high-risk profiles. Several risk factors have been identified in never-smoking lung cancer and one of the most important factor is a lung cancer family history (LCFH) in a first-degree relative. Other high-risk occupational or environmental factors include air-pollution exposed occupations (such as traffic policeman and street cleaners) for at least 10 years, cooking index ≥ 110, defined as 2/7 \* days cooking by pan frying, stir frying, or deep frying in one week \* years cooking, cooking without using ventilation, passive smoke exposure, and history of pulmonary tuberculosis or chronic obstructive pulmonary disorders. As described above, three high risk groups are interested in this study, the previous heavy smokers (group 1); those who has family history (group 2) and those who have high risk occupation or environment factors (group 3). From the published researches, we assume the detection rate to be 1.1% for group 1 based on NLST results16, 2.6% for group 2 (395 out of 12,011 subjects in TALENT), and we assume the detection Group 3 to be 1% after consulting board-certified senior specialists in this field. This is a prospective, multi-center, single arm study in Taiwan of subjects who are eligible to receive LDCT screening based on recommendation of Health Promotion Administration of Taiwan. The primary objective of TRIO part A is the LDCT screening acceptance rate of high lung cancer risk subjects. The primary objective of TRIO part B is the exact lung cancer detection rates in these three groups. Other secondary objectives are also included.
CONDITIONS
Official Title
Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Group 1: Previous heavy smokers aged 50 to 80 years who have smoked at least 20 pack-years and stopped smoking for more than 6 months but less than 15 years
- Group 2: First-degree relatives of lung cancer patients aged over 50 years, or younger than 50 but older than the age at diagnosis of the youngest lung cancer family member
- Group 3: Individuals aged 50 to 80 years with one or more high-risk factors including air-pollution exposed occupations for at least 10 years, cooking index of 110 or higher, cooking without ventilation for more than 20 years, or history of pulmonary tuberculosis treated more than 5 years ago
You will not qualify if you...
- Previous history of lung cancer
- Another malignancy within 5 years except cervical carcinoma in situ or non-melanomatous skin carcinoma
- Unable to tolerate transthoracic procedures or thoracotomy
- Chest CT examination performed within 18 months
- Hemoptysis of unknown cause within one month
- Unexplained weight loss over 6 kg in one year
- Known pregnancy
- Unable to understand or respond to the questionnaire even with help
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Chung Shan Medical University
Taichung, Taiwan, Taiwan, 402
Actively Recruiting
2
National Taiwan University Hospital Hsin-Chu Branch
Hsinchu, Taiwan
Actively Recruiting
3
Hualien Tzu Chi Hospital
Hualien City, Taiwan, 970473
Actively Recruiting
4
E-Da Hospital
Kaohsiung City, Taiwan
Not Yet Recruiting
5
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Actively Recruiting
6
Ministry of Health and Welfare Shuang-Ho Hospital
New Taipei City, Taiwan
Not Yet Recruiting
7
National Taiwan University Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
G
GeeChen Chang, MD. PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here